Metis Global Partners LLC Sells 371 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Metis Global Partners LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,142 shares of the biopharmaceutical company’s stock after selling 371 shares during the period. Metis Global Partners LLC’s holdings in Gilead Sciences were worth $5,210,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Manning & Napier Advisors LLC acquired a new stake in shares of Gilead Sciences in the second quarter worth $25,328,000. Legal & General Group Plc lifted its position in Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the last quarter. IRON Financial LLC bought a new stake in Gilead Sciences during the third quarter valued at about $830,000. Wealth Enhancement Advisory Services LLC grew its position in shares of Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after purchasing an additional 33,162 shares during the last quarter. Finally, Cetera Investment Advisers grew its holdings in Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after buying an additional 119,909 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 56,947 shares of company stock worth $4,968,674. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Down 0.1 %

Shares of NASDAQ:GILD opened at $92.52 on Thursday. The company has a 50 day moving average price of $86.22 and a two-hundred day moving average price of $75.69. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.82 and a current ratio of 1.11. The company has a market capitalization of $115.19 billion, a PE ratio of 1,029.22, a PEG ratio of 2.91 and a beta of 0.17. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. Analysts forecast that Gilead Sciences, Inc. will post 4.39 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Cantor Fitzgerald raised their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $93.10.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.